Delivery of vascular endothelial growth factor (VEGFC) via engineered exosomes improves lymphedema.

导出 LinkOut

翻译打印收藏纠错

作者： Bohan,Li ^[1] ; Jiantao,Yang ^[1] ; Raoping,Wang ^[2] ; Jia,Li ^[1] ; Xubo,Li ^[1] ; Xiang,Zhou ^[1] ; Shuai,Qiu ^[1] ; Ricong,Weng ^[1] ; Zichao,Wu ^[1] ; Chunyuan,Tang ^[2] ; Ping,Li ^[1]

作者单位： Department of Microsurgery & Orthopedic Trauma, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. ^[1] Department of Nephrology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. ^[2]

关键词 CD63 Lymphedema delivery system engineered exosomes vascular endothelial growth factor (VEGFC)

DOI 10.21037/atm-20-6605

PMID 33313243

发布时间 2022-04-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Annals of translational medicine

2020年8卷22期

1498页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Delivery of vascular endothelial growth factor (VEGFC) via engineered exosomes improves lymphedema.

Annals of translational medicine

相似文献

Annals of translational medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Delivery of vascular endothelial growth factor (VEGFC) via engineered exosomes improves lymphedema.

Annals of translational medicine

相似文献

Annals of translational medicine

相关期刊

检索历史清除